QIAGEN and AstraZeneca Expand Pact to Develop CDx in Chronic Diseases

QIAGEN N.V. (QGEN) has expanded its Master Collaboration Agreement with AstraZeneca (AZN) to develop and commercialize companion diagnostics (CDx) for AstraZeneca’s future therapies targeting chronic diseases. The collaboration will see QIAGEN developing and validating a genotyping assay using its QIAstat-Dx syndromic testing platform.The recent development is poised to enhance the company’s Molecular Diagnostics business.Significance of QIAGEN’s Expanded PartnershipThe new QIAstat-Dx genotyping assay, bein ...